172 related articles for article (PubMed ID: 32141310)
21. Healthcare Resource Utilization and Related Costs in Chronic Fibrosing Interstitial Lung Diseases with a Progressive Phenotype: A US Claims Database Analysis.
Olson AL; Hartmann N; Patnaik P; Garry EM; Bohn RL; Singer D; Baldwin M; Wallace L
Adv Ther; 2022 Apr; 39(4):1794-1809. PubMed ID: 35199282
[TBL] [Abstract][Full Text] [Related]
22. Health care costs and utilization of progressive fibrosing lung disease by underlying interstitial lung disease type.
Nili M; Steffens A; Anderson A; Brekke L; Grace Johnson M; Veeranki P; Olson AL
J Manag Care Spec Pharm; 2024 Feb; 30(2):163-174. PubMed ID: 38308627
[TBL] [Abstract][Full Text] [Related]
23. Burden of illness in progressive fibrosing interstitial lung disease.
Singer D; Bengtson LGS; Conoscenti CS; Anderson AJ; Brekke L; Shetty SS; Brown KK
J Manag Care Spec Pharm; 2022 Aug; 28(8):871-880. PubMed ID: 35876293
[No Abstract] [Full Text] [Related]
24. Acute exacerbation of interstitial lung disease after procedures.
Amundson WH; Racila E; Allen T; Dincer HE; Tomic R; Bhargava M; Perlman DM; Kim HJ
Respir Med; 2019 Apr; 150():30-37. PubMed ID: 30961948
[TBL] [Abstract][Full Text] [Related]
25. Clinical profile of unclassifiable interstitial lung disease: Comparison with chronic fibrosing idiopathic interstitial pneumonias.
Traila D; Oancea C; Tudorache E; Mladinescu OF; Timar B; Tudorache V
J Int Med Res; 2018 Jan; 46(1):448-456. PubMed ID: 28758849
[TBL] [Abstract][Full Text] [Related]
26. Comparison of clinical courses and mortality of connective tissue disease-associated interstitial pneumonias and chronic fibrosing idiopathic interstitial pneumonias.
Yıldırım F; Türk M; Bitik B; Erbaş G; Köktürk N; Haznedaroğlu Ş; Türktaş H
Kaohsiung J Med Sci; 2019 Jun; 35(6):365-372. PubMed ID: 30913371
[TBL] [Abstract][Full Text] [Related]
27. Progressive Fibrosing Interstitial Lung Diseases: Prevalence and Characterization in Two Italian Referral Centers.
Faverio P; Piluso M; De Giacomi F; Della Zoppa M; Cassandro R; Harari S; Luppi F; Pesci A
Respiration; 2020; 99(10):838-845. PubMed ID: 33264777
[TBL] [Abstract][Full Text] [Related]
28. Development of a scoring system with multidimensional markers for fibrosing interstitial lung disease.
Shi S; Chen L; Liu X; Yu M; Wu C; Xiao Y
Sci Rep; 2022 Aug; 12(1):14217. PubMed ID: 35987772
[TBL] [Abstract][Full Text] [Related]
29. The utility of the Japanese Association for Acute Medicine DIC scoring system for predicting survival in acute exacerbation of fibrosing idiopathic interstitial pneumonia.
Yamazaki R; Nishiyama O; Saeki S; Sano H; Iwanaga T; Tohda Y
PLoS One; 2019; 14(8):e0212810. PubMed ID: 31425562
[TBL] [Abstract][Full Text] [Related]
30. Association between Pepsin in Bronchoalveolar Lavage Fluid and Prognosis of Chronic Fibrosing Interstitial Lung Disease.
Kim Y; Lee YJ; Cho YJ; Yoon HI; Lee JH; Lee CT; Park JS
Tohoku J Exp Med; 2018 Nov; 246(3):147-153. PubMed ID: 30405002
[TBL] [Abstract][Full Text] [Related]
31. Clinical manifestations and prognostic factors analysis of patients hospitalised with acute exacerbation of idiopathic pulmonary fibrosis and other interstitial lung diseases.
Ba C; Wang H; Jiang C; Shi X; Jin J; Fang Q
BMJ Open Respir Res; 2024 Feb; 11(1):. PubMed ID: 38413119
[TBL] [Abstract][Full Text] [Related]
32. Clinical Significance of Interstitial Lung Disease and Its Acute Exacerbation in Microscopic Polyangiitis.
Hozumi H; Kono M; Hasegawa H; Yasui H; Suzuki Y; Karayama M; Furuhashi K; Enomoto N; Fujisawa T; Inui N; Nakamura Y; Yokomura K; Nakamura H; Suda T
Chest; 2021 Jun; 159(6):2334-2345. PubMed ID: 33571506
[TBL] [Abstract][Full Text] [Related]
33. Impact of lymphocyte differential count > 15% in BALF on the mortality of patients with acute exacerbation of chronic fibrosing idiopathic interstitial pneumonia.
Takei R; Arita M; Kumagai S; Ito Y; Noyama M; Tokioka F; Ishida T
BMC Pulm Med; 2017 Apr; 17(1):67. PubMed ID: 28427425
[TBL] [Abstract][Full Text] [Related]
34. Pulmonary artery enlargement predicts poor outcome during acute exacerbations of fibrotic interstitial lung disease.
Kogo M; Otsuka K; Morimoto T; Nagata K; Nakagawa A; Tomii K
Respirology; 2019 Aug; 24(8):777-782. PubMed ID: 30866125
[TBL] [Abstract][Full Text] [Related]
35. Incidence, risk factors, and prognosis of acute exacerbation of rheumatoid arthritis-associated interstitial lung disease: a systematic review and meta-analysis.
Xie M; Zhu C; Ye Y
BMC Pulm Med; 2023 Jul; 23(1):255. PubMed ID: 37434169
[TBL] [Abstract][Full Text] [Related]
36. Nationwide epidemiologic study for fibrosing interstitial lung disease (F-ILD) in South Korea: a population-based study.
Joung KI; Park H; Park S; Shin JY; Kim YH
BMC Pulm Med; 2023 Mar; 23(1):98. PubMed ID: 36949407
[TBL] [Abstract][Full Text] [Related]
37. Nintedanib: A Review in Fibrotic Interstitial Lung Diseases.
Lamb YN
Drugs; 2021 Apr; 81(5):575-586. PubMed ID: 33765296
[TBL] [Abstract][Full Text] [Related]
38. Clinical features of acute exacerbation in rheumatoid arthritis-associated interstitial lung disease: Comparison with idiopathic pulmonary fibrosis.
Otsuka J; Yoshizawa S; Kudo K; Osoreda H; Ishimatsu A; Taguchi K; Moriwaki A; Wakamatsu K; Iwanaga T; Yoshida M
Respir Med; 2022; 200():106898. PubMed ID: 35696743
[TBL] [Abstract][Full Text] [Related]
39. Fibrosing interstitial pneumonia predicts survival in patients with rheumatoid arthritis-associated interstitial lung disease (RA-ILD).
Solomon JJ; Ryu JH; Tazelaar HD; Myers JL; Tuder R; Cool CD; Curran-Everett D; Fischer A; Swigris JJ; Brown KK
Respir Med; 2013 Aug; 107(8):1247-52. PubMed ID: 23791462
[TBL] [Abstract][Full Text] [Related]
40. Low forced vital capacity predicts cytotoxic chemotherapy-associated acute exacerbation of interstitial lung disease in patients with lung cancer.
Enomoto Y; Inui N; Kato T; Baba T; Karayama M; Nakamura Y; Ogura T; Suda T
Lung Cancer; 2016 Jun; 96():63-7. PubMed ID: 27133752
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
